Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.50 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 10/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14753817 | 0.86 | P2RX7 (0.45) | P2RX7CNR2IL1BCNR1SMN1; SMN2 | |
| SCHEMBL14736751 | 0.86 | P2RX7 (0.50) | P2RX7IL1B | |
| SCHEMBL14750832 | 0.84 | P2RX7 (0.43) | P2RX7CNR2IL1BCNR1SMN1; SMN2 | |
| SCHEMBL1019863 | 0.84 | P2RX7 (0.70) | P2RX7IL1B | |
| SCHEMBL1021245 | 0.82 | P2RX7 (0.56) | P2RX7CNR2IL1BCNR1 | |
| SCHEMBL1020461 | 0.82 | P2RX7 (0.56) | P2RX7CNR2IL1BCNR1 | |
| SCHEMBL14750830 | 0.81 | P2RX7 (0.46) | P2RX7SMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL1019758 | 0.75 | P2RX7 (0.58) | P2RX7CNR2IL1BCNR1 | |
| SCHEMBL1018878 | 0.73 | P2RX7 (0.56) | P2RX7CNR2IL1BCNR1 | |
| SCHEMBL1018232 | 0.73 | P2RX7 (0.50) | P2RX7CNR2IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | AFFECTIS PHARMACEUTICALS AG (DE) | 2013-03-07 | — | — | US | disclosed |
| EP-2386541-A1 | Novel methods for the preparation of P2X7R antagonists | Affectis Pharmaceuticals AG (DE) | 2011-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060047-A1 | NOVEL METHODS FOR THE PREPARATION OF P2X7R ANTAGONISTS | P2RX7, P2RX3, P2RX2 | P2RX7 1/4885CNR2 22/4885IL1B 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.